Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of Alberta

$17,500.00

The mechanisms behind the beneficial effects of Dapagliflozin in the failing heart by providing an extra source of fuel as ketones

EF 2019-20

Résumé
"Cardiovascular diseases (CVD), especially heart failure, are a leading cause of death in Canadians and have substantial effects on the health care system and individuals' quality of life. Type 2 diabetes (T2D0 is a significant risk factor for the development of heart failure, and the presence of both T2D and CVD increases the risk for cardiovascular mortality. Sodium glucose co-transporter 2 inhibitors (SGLT2i), a class of anti-diabetic drugs,, have shown cardioprotective effects in improving heart failure outcomes in both T2D and non T2D patients at high risk for cardiovascular events in clinical trials involving both the SGLT2i Empagliflozin and Dapagliflozin. However, the exact mechanisms responsible for their beneficial cardioprotective effects are not clear, and only few studies have examined this in a non T2D model of heart failure. The failing heart has a 'starved' energy profile with decreased energy production. SGLT2i have been shown to increase ketone body levels in the bloodstream: another energy fuel source, and studies have shown that the failing heart increases ketone body oxidation. Therefore, we hypothesize that ketone body oxidation may be a mediator of the beneficial cardioprotective effects of SGLT2i in the failing heart. Through providing additional fuel, the total energy production in the failing heart would increase, resulting in improved cardiac outcomes. This proposed study will help elucidate the specific pathways on which the SGLT2i Dapagliflozin acts and determine whether increased cardiac ketone body oxidation plays a role. Results from the study will be beneficial in developing a targeted unique approach to treating heart failure. "
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Alberta, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
429135
Name
Pherwani Simran A
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
The mechanisms behind the beneficial effects of Dapagliflozin in the failing heart by providing an extra source of fuel as ketones
Programtype2
Studentship Programs
Orgnameinp2
University of Alberta
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cardiac Energy Metabolism; Heart Failure; Ketone Bodies; Ketone Body Metabolism; Sglt2 Inhibitors; Type 2 Diabetes
Abstract
"Cardiovascular diseases (CVD), especially heart failure, are a leading cause of death in Canadians and have substantial effects on the health care system and individuals' quality of life. Type 2 diabetes (T2D0 is a significant risk factor for the development of heart failure, and the presence of both T2D and CVD increases the risk for cardiovascular mortality. Sodium glucose co-transporter 2 inhibitors (SGLT2i), a class of anti-diabetic drugs,, have shown cardioprotective effects in improving heart failure outcomes in both T2D and non T2D patients at high risk for cardiovascular events in clinical trials involving both the SGLT2i Empagliflozin and Dapagliflozin. However, the exact mechanisms responsible for their beneficial cardioprotective effects are not clear, and only few studies have examined this in a non T2D model of heart failure. The failing heart has a 'starved' energy profile with decreased energy production. SGLT2i have been shown to increase ketone body levels in the bloodstream: another energy fuel source, and studies have shown that the failing heart increases ketone body oxidation. Therefore, we hypothesize that ketone body oxidation may be a mediator of the beneficial cardioprotective effects of SGLT2i in the failing heart. Through providing additional fuel, the total energy production in the failing heart would increase, resulting in improved cardiac outcomes. This proposed study will help elucidate the specific pathways on which the SGLT2i Dapagliflozin acts and determine whether increased cardiac ketone body oxidation plays a role. Results from the study will be beneficial in developing a targeted unique approach to treating heart failure. "
Competitiondate
201912
Approvedterm2
1 yr 0 mth
Pinamesdelim
Pherwani, Simran A
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~